BackMolecular Pharmacology (USA), Overview

Molecular Pharmacology (USA), Long Term Debt

Latest long-term debt for MLPH: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Molecular Pharmacology (USA), Long Term Debt History

Loading

Molecular Pharmacology (USA), vs. peers: Long Term Debt Comparison

Loading

Molecular Pharmacology (USA), Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Molecular Pharmacology (USA), (MLPH) FAQ

As of the most recent data (September 2014), MLPH shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MLPH's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Molecular Pharmacology (USA), is outperforming or lagging.

Tracking MLPH's long-term debt over time shows whether Molecular Pharmacology (USA), is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Molecular Pharmacology (USA),'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.